4.6 Article

Validation of the simplified modified Rankin scale for stroke trials: Experience from the ENCHANTED alteplase-dose arm

Journal

INTERNATIONAL JOURNAL OF STROKE
Volume 16, Issue 2, Pages 222-228

Publisher

SAGE PUBLICATIONS LTD
DOI: 10.1177/1747493019897858

Keywords

Simplified modified Rankin scale questionnaire; modified Rankin scale; ischemic stroke; clinical trial; health outcome

Funding

  1. National Health and Medical Research Council (NHMRC) of Australia [1020462, 1101113]
  2. Stroke Association of the United Kingdom [TSA 2012/01, 2015/01]
  3. Ministry of Health
  4. National Council for Scientific and Technological Development of Brazil (CNPQ) [467322/2014-7, 402388/2013-5]
  5. Ministry for Health, Welfare and Family Affairs of the Republic of Korea [HI14C1985]
  6. NHMRC Career Development Fellowship Level 2 [APP1141328]
  7. NHMRC Senior Principal Research Fellowship
  8. National Health and Medical Research Council of Australia [1101113] Funding Source: NHMRC

Ask authors/readers for more resources

The study demonstrates the utility of the structured, simplified modified Rankin scale questionnaire in acute stroke research, showing high reliability and agreement with the standard modified Rankin scale. It can be used as a reliable alternative measure of functional status after acute ischemic stroke.
Background and aims The structured, simplified modified Rankin scale questionnaire (smRSq) may increase reliability over the interrogative approach to scoring the modified Rankin scale (mRS) in acute stroke research and practice. During the conduct of the alteplase-dose arm of the international ENhanced Control of Hypertension ANd Thrombolysis StrokE stuDy (ENCHANTED), we had an opportunity to compare each of these approaches to outcome measurement. Methods Baseline demographic data were recorded together with the National Institutes of Health Stroke Scale (NIHSS). Follow-up measures obtained at 90 days included mRS, smRSq, and the 5-Dimension European Quality of life scale (EQ-5D). Agreements between smRSq and mRS were assessed with the Kappa statistic. Multiple logistic regression was used to identify baseline predictors of Day 90 smRSq and mRS scores. Treatment effects, based on Day 90 smRSq/mRS scores, were tested in logistic and ordinal logistic regression models. Results SmRSq and mRS scores had good agreement (weighted Kappa 0.79, 95% confidence interval (CI) 0.78-0.81), while variables of age, atrial fibrillation, diabetes mellitus, pre-morbid mRS (1 vs. 0), baseline NIHSS scores, and imaging signs of cerebral ischemia, similarly predicted their scores. Odds ratios for death or disability, and ordinal shift, 90-day mRS scores using smRSq were 1.05 (95% CI 0.91-1.20; one-sided P = 0.23 for non-inferiority) and 0.98 (95% CI 0.87-1.11; P = 0.02 for non-inferiority), similar to those using mRS. Conclusions This study demonstrates the utility of the smRSq in a large, ethnically diverse clinical trial population. Scoring of the smRSq shows adequate agreement with the standard mRS, thus confirming it is a reliable, valid, and useful alternative measure of functional status after acute ischemic stroke.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available